Unichem recalls one lot of hypertension drug in US

The drug was recalled due to the identification of another tablet in a bottle of the product

Press Trust of India New Delhi
Last Updated : Aug 03 2015 | 8:32 AM IST
Drug firm Unichem Laboratories is recalling one lot of Hydrochlorothiazide tablets, used to treat high blood pressure, in the US market due to the identification of another tablet in a bottle of the product.

Unichem Pharmaceuticals (USA), Inc, a wholly-owned subsidiary of the company, is voluntarily recalling one lot of Hydrochlorothiazide Tablets 25 mg 1000-count bottle at the consumer level, US Food and Drug Administration (USFDA) said in a statement.

"This recall has been initiated as a precautionary measure due to the identification of a Clopidogrel tablet found in a bottle of the product," it added.

Also Read

The risk associated with mistakenly taking a Clopidogrel tablet instead of a Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel's side effects which include bleeding and/or bruising, the US health regulator said.

Patients with active bleeding or who are allergic to Clopidogrel or any component of the formulation may experience more serious adverse health consequences as a result of unknowingly consuming Clopidogrel, it said.

Additionally, missing a dose of Hydrochlorothiazide could result in uncontrolled blood pressure or swelling caused by excess fluid, it added.

"As per Unichem's internal investigation, this episode is an isolated event noted at one pharmacy and confined to the recalled lot," USFDA said.

Unichem has not received any reports of adverse events related to this recall to date, it added.

Hydrochlorothiazide tablets are indicated for the management of high blood pressure and edema and are packaged in 1000-count bottles.

The affected lot of Hydrochlorothiazide tablets was distributed nationwide directly to wholesalers, retailers, and pharmacies from May 21-28, 2015.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 03 2015 | 4:57 AM IST

Next Story